Gestational iron deficiency anemia is associated with preterm birth, fetal growth restriction, and postpartum infections

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Lotta Kemppinen ◽  
Mirjami Mattila ◽  
Eeva Ekholm ◽  
Nanneli Pallasmaa ◽  
Ari Törmä ◽  
...  
Keyword(s):  
Preterm Birth ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Iron Supplementation ◽  
Reference Group ◽  
Intravenous Iron ◽  
Growth Restriction ◽  
Neonatal Outcomes ◽  
Maternal And Neonatal Outcomes ◽  
Intravenous Iron Supplementation

AbstractObjectivesGestational IDA has been linked to adverse maternal and neonatal outcomes, but the impact of iron supplementation on outcome measures remains unclear. Our objective was to assess the effects of gestational IDA on pregnancy outcomes and compare outcomes in pregnancies treated with either oral or intravenous iron supplementation.MethodsWe evaluated maternal and neonatal outcomes in 215 pregnancies complicated with gestational IDA (Hb<100 g/L) and delivered in our tertiary unit between January 2016 and October 2018. All pregnancies from the same period served as a reference group (n=11,545). 163 anemic mothers received oral iron supplementation, and 52 mothers received intravenous iron supplementation.ResultsGestational IDA was associated with an increased risk of preterm birth (10.2% vs. 6.1%, p=0.009) and fetal growth restriction (FGR) (1.9% vs. 0.3%, p=0.006). The gestational IDA group that received intravenous iron supplementation had a greater increase in Hb levels compared to those who received oral medication (18.0 g/L vs. 10.0 g/L, p<0.001), but no statistically significant differences in maternal and neonatal outcomes were detected.ConclusionsCompared to the reference group, prematurity, FGR, postpartum infections, and extended hospital stays were more common among mothers with gestational IDA, causing an additional burden on the families and the healthcare system.

scholarly journals Fetal Growth Restriction as the Initial Finding of Preeclampsia is a Clinical Predictor of Maternal and Neonatal Prognoses: A Single-center Retrospective Study

2021 ◽  
Author(s):  
Masaya Takahashi ◽  
Shintaro Makino ◽  
Kyoko Oguma ◽  
Haruka Imai ◽  
Ai Takamizu ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Neonatal Outcomes ◽  
Hypertensive Disorder ◽  
Initial Finding ◽  
Neonatal Complications ◽  
Maternal And Neonatal Outcomes ◽  
New Criteria

Abstract Background: Preeclampsia (PE) is a hypertensive disorder specific to pregnancy, which sometimes causes severe maternal-neonatal complications. The International Society for the Study of Hypertension in Pregnancy revised their criteria for PE in 2018; a PE diagnosis can be established in the absence of proteinuria when other specific symptoms exist, such as other organ dysfunction or uteroplacental dysfunction. Therefore, the initial findings of PE (IFsPE) at the first diagnosis can vary considerably across patients. However, there are no reports on patients with PE based on different IFsPE and their impact on patients’ clinical outcomes. Thus, we aimed to investigate the predictors of maternal and neonatal outcomes based on IFsPE according to the new criteria.Methods: This was a retrospective study involving 3729 women who delivered at our hospital between 2015 and 2019. All women were reclassified based on the new criteria. They were divided into three groups based on the IFsPE: Classification 1 (C-1), proteinuria (classical criteria); Classification 2 (C-2), damage to other maternal organs; and Classification 3 (C-3), uteroplacental dysfunction. Maternal and fetal conditions and perinatal outcomes were assessed in the three groups.Results: In total, 104 women with PE were included. Of those, 42 (40.4%), 28 (26.9%), and 34 (32.7%) were assigned to C-1, C-2, and C-3 groups, respectively. All women in C-3 showed fetal growth restriction (FGR). The number of gestational weeks at PE diagnosis and delivery was significantly lower in the C-3 group (C-1, 35.5±3.0 weeks; C-2, 35.2±3.6 weeks; C-3, 31.6±4.6 weeks, P < 0.01; and C-1, 36.8±2.8 weeks; C-2, 36.3±3.2 weeks; C-3, 33.4±4.4 weeks, P < 0.01, respectively). The rates of preterm delivery at < 34 weeks (odds ratio [OR]=4.58 [1.74-12.10] and OR=2.83 [1.01-7.97]), cesarean delivery (OR=4.35 [1.41-13.45] and OR=5.03 [1.51-16.78]), Apgar scores < 7 at 1 min (OR=6.58 [2.08-20.80] and OR=4.09 [1.26-13.29]), neonatal intensive care unit admission (OR=12.19 [3.62-41.08], OR=7.50 [2.09-26.96]), and composite neonatal complications (OR=6.58 [2.08-20.80] and OR=5.33 [1.52-18.70]) were significantly higher in the C-3 group than in the C-1 and C-2 groups.Conclusions: PE patients with FGR had the most unfavorable prognosis for both maternal and neonatal outcomes.

423: Does fetal growth restriction predict adverse maternal and neonatal outcomes in women with preeclampsia?

2015 ◽  
Vol 212 (1) ◽  
pp. S219-S220
Author(s):  
Kathryn Sharma ◽  
Tania Esakoff ◽  
Alyson Guillet ◽  
Richard Burwick ◽  
Aaron Caughey
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Neonatal Outcomes ◽  
Maternal And Neonatal Outcomes

824 Prediction of perinatal demise and severe adverse neonatal outcomes in pregnancies with fetal growth restriction

2021 ◽  
Vol 224 (2) ◽  
pp. S513-S514
Author(s):  
Emily W. Zantow ◽  
Jennifer E. Powel ◽  
Samantha J. Mullan ◽  
Megan L. Lawlor ◽  
Kia Lannaman ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Neonatal Outcomes ◽  
Adverse Neonatal Outcomes

Placental Pathologic Changes Associated with Fetal Growth Restriction and Consequent Neonatal Outcomes

2020 ◽  
pp. 1-12
Author(s):  
Do Hwa Im ◽  
Young Nam Kim ◽  
Hwa Jin Cho ◽  
Yong Hee Park ◽  
Da Hyun Kim ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Neonatal Outcomes

scholarly journals Effect of Endogenic and Exogenic Oxidative Stress Triggers on Adverse Pregnancy Outcomes: Preeclampsia, Fetal Growth Restriction, Gestational Diabetes Mellitus and Preterm Birth

2021 ◽  
Vol 22 (18) ◽  
pp. 10122
Author(s):  
Eun Hui Joo ◽  
Young Ran Kim ◽  
Nari Kim ◽  
Jae Eun Jung ◽  
Seon Ha Han ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Diabetes Mellitus ◽  
Preterm Birth ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Fetal Growth ◽  
Pregnancy Outcomes ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Adverse Pregnancy

Oxidative stress is caused by an imbalance between the production of reactive oxygen species (ROS) in cells and tissues and the ability of a biological system to detoxify them. During a normal pregnancy, oxidative stress increases the normal systemic inflammatory response and is usually well-controlled by the balanced body mechanism of the detoxification of anti-oxidative products. However, pregnancy is also a condition in which this adaptation and balance can be easily disrupted. Excessive ROS is detrimental and associated with many pregnancy complications, such as preeclampsia (PE), fetal growth restriction (FGR), gestational diabetes mellitus (GDM), and preterm birth (PTB), by damaging placentation. The placenta is a tissue rich in mitochondria that produces the majority of ROS, so it is important to maintain normal placental function and properly develop its vascular network to ensure a safe and healthy pregnancy. Antioxidants may ameliorate these diseases, and related research is progressing. This review aimed to determine the association between oxidative stress and adverse pregnancy outcomes, especially PE, FGR, GDM, and PTB, and explore how to overcome this oxidative stress in these unfavorable conditions.

Sign in / Sign up

Export Citation Format

Share Document